Severe Worsening of Neuropathy Associated With Antibodies Against Myelin-Associated Glycoprotein by Rituximab Resembling Chronic Inflammatory Demyelinating Polyneuropathy

利妥昔单抗引起的抗髓鞘相关糖蛋白抗体相关神经病变严重恶化,类似于慢性炎症性脱髓鞘性多发性神经病

阅读:1

Abstract

The presence of antibodies against myelin-associated glycoprotein (anti-MAG) is typically associated with distal acquired demyelinating symmetric neuropathy (DADS), usually presenting with slowly evolving sensory more than motor distal predominant polyneuropathy. On electrodiagnostic testing, DADS tends to show findings indicating distal predominant demyelination. Despite being a predominantly demyelinating neuropathy, DADS is resistant to multiple immunotherapies. Rituximab has been used as a successful treatment in a portion of patients with DADS, but rare cases of worsening of anti-MAG neuropathy have also been previously described. Here we describe a male patient with DADS who possessed high-titer anti-MAG antibodies. However, immediately following two doses of rituximab, he demonstrated a significant deterioration with acute proximal limb weakness and positive response to treatment of corticosteroid and intravenous immunoglobulin, resembling chronic inflammatory demyelinating polyneuropathy (CIDP).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。